Cargando…
In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer
Cancer is one of the most lethal diseases in the world, and the development and improvement of treatments used in cancer therapies are extremely important for a better quality of life for patients. In view of the current problems in drug administration such as low solubility and adverse effects, the...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370415/ https://www.ncbi.nlm.nih.gov/pubmed/35956870 http://dx.doi.org/10.3390/molecules27154920 |
_version_ | 1784766789932023808 |
---|---|
author | Paiva, Karen L. R. Radicchi, Marina A. Báo, Sônia N. |
author_facet | Paiva, Karen L. R. Radicchi, Marina A. Báo, Sônia N. |
author_sort | Paiva, Karen L. R. |
collection | PubMed |
description | Cancer is one of the most lethal diseases in the world, and the development and improvement of treatments used in cancer therapies are extremely important for a better quality of life for patients. In view of the current problems in drug administration such as low solubility and adverse effects, the activity of a solid lipid nanoparticle containing docetaxel (SLN-DTX), a drug already used in conventional therapies, was evaluated in a cell line (MDA-MB-231) of one of the most aggressive types of breast cancer with the worst prognosis, triple-negative breast cancer. Viability tests indicated that SLN-DTX has a greater dependence on the treatment dose when compared to the free drug, which indicates a more controlled release of the drug, and both reduced viability by around 50% at a concentration of 1 µg/mL after 72 h. Transmission electron microscopy (TEM) and confocal and light microscopy analyses indicated that after treatment the cells enter a mitotic catastrophe, characteristic of antimitotic drugs that usually make cells progress to death or senescence. Cells treated with both DTX and SLN-DTX showed significant inhibition of mobility, 73.6% and 66.5% when treated with SLN-DTX and DTX, respectively, compared to the 11.4% of the control after 72 h, characteristics that are very relevant in tumor development and progression. SLN-DTX demonstrated its great potential as a nanocarrier by maintaining and improving the drug’s action in the MDA-MB-231 cell line. |
format | Online Article Text |
id | pubmed-9370415 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93704152022-08-12 In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer Paiva, Karen L. R. Radicchi, Marina A. Báo, Sônia N. Molecules Article Cancer is one of the most lethal diseases in the world, and the development and improvement of treatments used in cancer therapies are extremely important for a better quality of life for patients. In view of the current problems in drug administration such as low solubility and adverse effects, the activity of a solid lipid nanoparticle containing docetaxel (SLN-DTX), a drug already used in conventional therapies, was evaluated in a cell line (MDA-MB-231) of one of the most aggressive types of breast cancer with the worst prognosis, triple-negative breast cancer. Viability tests indicated that SLN-DTX has a greater dependence on the treatment dose when compared to the free drug, which indicates a more controlled release of the drug, and both reduced viability by around 50% at a concentration of 1 µg/mL after 72 h. Transmission electron microscopy (TEM) and confocal and light microscopy analyses indicated that after treatment the cells enter a mitotic catastrophe, characteristic of antimitotic drugs that usually make cells progress to death or senescence. Cells treated with both DTX and SLN-DTX showed significant inhibition of mobility, 73.6% and 66.5% when treated with SLN-DTX and DTX, respectively, compared to the 11.4% of the control after 72 h, characteristics that are very relevant in tumor development and progression. SLN-DTX demonstrated its great potential as a nanocarrier by maintaining and improving the drug’s action in the MDA-MB-231 cell line. MDPI 2022-08-02 /pmc/articles/PMC9370415/ /pubmed/35956870 http://dx.doi.org/10.3390/molecules27154920 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Paiva, Karen L. R. Radicchi, Marina A. Báo, Sônia N. In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer |
title | In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer |
title_full | In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer |
title_fullStr | In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer |
title_full_unstemmed | In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer |
title_short | In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer |
title_sort | in vitro evaluation of nls-dtx activity in triple-negative breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370415/ https://www.ncbi.nlm.nih.gov/pubmed/35956870 http://dx.doi.org/10.3390/molecules27154920 |
work_keys_str_mv | AT paivakarenlr invitroevaluationofnlsdtxactivityintriplenegativebreastcancer AT radicchimarinaa invitroevaluationofnlsdtxactivityintriplenegativebreastcancer AT baosonian invitroevaluationofnlsdtxactivityintriplenegativebreastcancer |